Balyasny Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-35,859
Closed -$4.86M 3012
2024
Q4
$4.74M Buy
+35,859
New +$5.04M 0.01% 1311
2024
Q2
Sell
-89,636
Closed -$12M 2810
2024
Q1
$12.3M Buy
89,636
+14,005
+19% +$1.91M 0.02% 833
2023
Q4
$10.3M Buy
75,631
+38,214
+102% +$4.66M 0.02% 852
2023
Q3
$4.58M Buy
37,417
+18,068
+93% +$2.3M 0.01% 1133
2023
Q2
$2.46M Buy
19,349
+15,438
+395% +$2.01M 0.01% 1316
2023
Q1
$505K Buy
+3,911
New +$512K ﹤0.01% 1955
2022
Q3
Sell
-142,899
Closed -$16.8M 3023
2022
Q2
$16.8M Buy
142,899
+10,834
+8% +$1.29M 0.05% 481
2022
Q1
$17.2M Buy
+132,065
New +$17.2M 0.05% 478
2021
Q4
Sell
-128,340
Closed -$20.8M 2403
2021
Q3
$20.8M Buy
+128,340
New +$21.6M 0.09% 333

Other funds holding IBB

Balyasny Asset Management's IBB Position: Q1 2025 in Review

Balyasny Asset Management sold out of iShares Biotechnology ETF (IBB) in Q1 2025, closing a stake of 35,859 shares — an estimated $4.86M sold.

Balyasny Asset Management first reported a position in IBB in Q3 2021 and held it in 9 quarters. The position peaked at $20.8M in Q3 2021. 831 funds tracked by Wall St. Rank hold IBB as of Q1 2025.

  • Balyasny Asset Management reported no remaining iShares Biotechnology ETF position as of Q1 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 35,859 iShares Biotechnology ETF shares in Q1 2025, an estimated $4.86M.
  • Balyasny Asset Management first reported a position in iShares Biotechnology ETF in Q3 2021 and held it in 9 quarters.
  • Balyasny Asset Management's iShares Biotechnology ETF position peaked at $20.8M in Q3 2021.
  • 831 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.